New York – July 20, 2015 – Cooley advised the underwriters on Catabasis Pharmaceuticals, Inc.'s $69 million initial public offering. Catabasis is a Massachusetts-based, clinical-stage biopharmaceutical company focused on the discovery and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted ("SMART") linker technology platform. The SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating multiple targets in one or more related disease pathways. The company's common stock trades on The NASDAQ Global Market under the symbol "CATB."
Citigroup Capital Markets Inc. and Cowen and Company, LLC acted as joint book-running managers for the offering. Oppenheimer & Co. Inc. and Wedbush PacGrow acted as co-managers.
The Cooley corporate securities team representing the underwriters included partners Div Gupta, Darren DeStefano and Brent Siler and associates Ali Haggerty and Danielle Gershowitz.
Support for the offering was provided by partners Wendy Goldstein and Natasha Leskovsek, special counsel Phil Mitchell and associate Leah Roffman (health care and life sciences regulatory); partners Ivor Elrifi and Bill Christiansen (intellectual property); partner Susan Cooper Philpot (tax); and associate Megan Arthur (compensation and benefits).
About Cooley LLP
High-growth and established companies, investors and investment banks focused on technology and life sciences partner with Cooley on transformative deals and high-stakes matters, where innovation meets the law.
Cooley has 850 lawyers across 12 offices in the United States, China and Europe.